Pure Global
NCT06221059

Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

A Phase II Clinical Study of Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in the Treatment of Patients With Chronic Kidney Disease (Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Design)
Shandong Suncadia Medicine Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Kidney Disease
Drug/Device/Intervention
HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shandong Suncadia Medicine Co., Ltd.
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2024
End date
Apr 01, 2025
Enrollment
180 participants
Primary outcome

Change From Baseline to Week 13 in UACR

Summary

The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin
 Proline tablets in patients with chronic kidney disease by evaluating UACR change from
 baseline to Week 13

ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06221059
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06221059 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.